Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Global Biosimilars Market Research Report 2022: Strong Pipeline of Drugs, Low Cost of Biosimilars and an Increase in Patent Expiration

Published

on

Dublin, Sept. 01, 2022 (GLOBE NEWSWIRE) — The “Biosimilars Global Market Opportunities And Strategies To 2031” report has been added to ResearchAndMarkets.com’s offering.

The global biosimilars market reached a value of nearly $11,418.9 million in 2021, having grown at a compound annual growth rate (CAGR) of 34.8% since 2016. The market is expected to grow from $11,418.9 million in 2021 to $25,985.2 million in 2026 at a rate of 17.3%. The market is then expected to grow at a CAGR of 18.0% from 2026 and reach $59,555.8 million in 2031.

This report describes and explains the biosimilars market and covers 2016-2021, termed the historic period, and 2021-2026 termed the forecast period, along with further forecasts for the period 2026-2031. The report evaluates the market across each region and for the major economies within each region.

Growth in the historic period resulted from an increase in cancer prevalence, strong economic growth in emerging markets, an increase in pharmaceutical R&D expenditure, increased healthcare expenditure, growing government initiatives, strong pipeline of drugs, low cost of biosimilars and an increase in patent expiration.

Factors that negatively affected growth in the historic period were regulatory changes, low healthcare access, lack of awareness on biosimilars among primary care physicians and specialists, reimbursement challenges, the coronavirus pandemic and low healthcare reimbursements.

Going forward, increasing prevalence of cancer, increasing demand for prophylaxis with granulocyte colony-stimulating factor (G-CSF), a rise in healthcare expenditure, high potential of emerging economies, technology advances, high penetration of biological drugs, aging population and an increase in healthcare access will drive the growth. Factors that could hinder the growth of the biosimilars market in the future include high costs of drugs, high cost of drug development with threat of failure, pricing pressures from regulators and insufficient and outdated health system.

The biosimilars market is segmented by type into monoclonal antibodies, insulin, erythropoietin, granulocyte-colony stimulating factor, other hormones and others. The monoclonal antibodies market was the largest segment of the biosimilars market segmented by type, accounting for 39.6% of the total in 2021. Going forward, the erythropoietin segment is expected to be the fastest growing segment in the biosimilars market segmented by type, at a CAGR of 28.2% during 2021-2026.

The biosimilars market is also segmented by application into oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and other applications. The chronic and autoimmune diseases market was the largest segment of the biosimilars market segmented by application, accounting for 45.6% of the total in 2021. Going forward, infectious diseases segment is expected to be the fastest growing segment in the biosimilars market segmented by end-user, at a CAGR of 24.8% during 2021-2026.

Western Europe was the largest region in the biosimilars market, accounting for 66.0% of the total in 2021. It was followed by North America, and then the other regions. Going forward, the fastest-growing regions in the biosimilars market will be Africa and Eastern Europe where growth will be at CAGRs of 117.0% and 60.1% respectively. These will be followed by South America and Middle East where the markets are expected to grow at CAGRs of 53.854% and 53.851% respectively.

The global biosimilars market is concentrated, with a small number of large players in the market. The top ten competitors in the market made up to 76.98% of the total market in 2021. The market concentration can be attributed to the high barriers to entry in terms of high costs associated with the research and development of pegfilgrastim biosimilars and the stringent regulations set up by the regulatory authorities.

Going forward the market is expected some fragmentation with the rising number of new entrants. Amgen was the largest competitor with 21.23% of the market, followed by Pfizer with 13.37%, Novartis AG with 10.13%, Samsung Bioepis Co., Ltd. with 9.90%, Viatris with 7.37%, Biocon with 3.60%, Celltrion, Inc. with 3.24%, Coherus Biosciences with 4.17%, Elli Lilly and Company with 1.99%, and Dr. Reddy’s Laboratories with 1.98%.

The top opportunities in the biosimilars market segmented by type will arise in the monoclonal antibodies segment, which will gain $8,508.0 million of global annual sales by 2026. The top opportunities in the biosimilars market segmented by application will arise in the oncology segment, which will gain $6,889.0 million of global annual sales by 2026. The biosimilars market size will gain the most in the USA at $6,677.4 million.

Market-trend-based strategies for the biosimilars market include focus on robust R&D activities for the development of effective and innovative drugs, focus on focus on M&A growth strategies, focus on establishing strategic partnerships, focus on increasing investments and focus on artificial intelligence.

Player-adopted strategies in the biosimilars market include strengthening product portfolio by new products launches, focusing on expansion strategies in different geographies and increasing research and development for new product development by collaborating with companies having same business.

To take advantage of the opportunities, the publisher recommends the biosimilars companies to launch new products, invest in robotics and artificial intelligence (AI), expand in emerging markets, scale up through merger and acquisition activity, provide competitively priced offerings, continue to participate in events and conferences, take initiatives to educate consumers, target high-growth application areas and increase strategic partnerships.

Key Topics Covered:

1. Biosimilars Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction and Market Characteristics
6.1. General Market Definition
6.2. Summary
6.3. Market Segmentation By Type
6.3.1. Monoclonal Antibodies
6.3.2. Insulin
6.3.3. Erythropoietin
6.3.4. Granulocyte-Colony Stimulating Factor
6.3.5. Other Hormones
6.3.6. Other Types
6.4. Market Segmentation By Application
6.4.1. Oncology
6.4.2. Chronic and Autoimmune Diseases
6.4.3. Growth Hormone Deficiency
6.4.4. Infectious Diseases
6.4.5. Other Applications

7. Major Market Trends
7.1. Robust Research & Development
7.2. Demand For Biosimilars In The Treatment Of Neutropenia
7.3. Growing Mergers And Acquisitions
7.4. Revised FDA Regulations To Facilitate Biosimilar Drug Development
7.5. Large Number Of Strategic Partnerships
7.6. Increasing Investments In Biosimilars Market
7.7. Use of Robots and AI

8. Global Market Size And Growth
8.1. Market Size
8.2. Historic Market Growth, 2016 – 2021, Value ($ Million)
8.2.1. Market Drivers 2016 – 2021
8.2.2. Market Restraints 2016 – 2021
8.3. Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)
8.3.1. Market Drivers 2021 – 2026
8.3.2. Market Restraints 2021 – 2026

9. Global Biosimilars Market Segmentation
9.1. Global Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
9.2. Global Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

10. Biosimilars Market, Regional And Country Analysis
10.1. Global Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
10.2. Global Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

Companies Mentioned

  • AbCellera
  • Adello Biologics
  • Alvotech
  • Amgen
  • Amneal Pharmaceuticals
  • Astellas
  • Biocon Biologics
  • Bristol-Myers Squibb
  • C-Bridge Capital
  • Celgene Corporation
  • Celltrion
  • ChrysCapital
  • Fresenius Kabi
  • Fuji Pharma Co., Ltd.
  • Hisun BioRay Bio-pharmaceutical Co., Ltd.
  • Impax Laboratories
  • Intas Pharmaceuticals
  • Japanese JV
  • Kashiv Pharma
  • Ligand Pharmaceuticals
  • PAG
  • Pfenex
  • Pfizer Healthcare India
  • Samsung Bioepis
  • Sandoz
  • Shire Plc
  • Takeda Pharmaceutical
  • TetraGenetics
  • True North
  • Viatris Biosimilars Business
  • mAbxience

For more information about this report visit https://www.researchandmarkets.com/r/rpdfbu

Attachment


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

CUBE acquires global regulatory intelligence businesses from Thomson Reuters

Published

on

cube-acquires-global-regulatory-intelligence-businesses-from-thomson-reuters

LONDON, May 17, 2024 /PRNewswire/ — CUBE, a global leader in Automated Regulatory Intelligence (ARI) and Regulatory Change Management (RCM), announces today its acquisition of the Thomson Reuters Regulatory Intelligence and Oden products and businesses.

The acquisition of these global businesses represents a major step forward in CUBE’s growth plans. It will deliver significant scale across many of the world’s leading and systemically important financial institutions. CUBE’s existing global customer base will be expanded to total approximately 1,000 customers in banking, insurance, asset and investment management, payments and adjacent regulated industries.
CUBE’s global employees will expand to 600, of which close to 250 are highly qualified regulatory subject matter experts, legal and compliance professionals.
Ben Richmond, founder and CEO of CUBE said: “Thomson Reuters is known to be the biggest and best in the industry for providing regulatory expert analysis and subject matter expertise, alongside world-leading journalism and news. The combination of CUBE’s purpose-built AI, with the years of content curated by Thomson Reuters Regulatory Intelligence and Oden expert analysts, will accelerate innovation. Together, we will deliver regulatory transformation capabilities for our global customers that could only have been imagined before.”
Richmond continues: “This combination will provide tremendous scale and depth across CUBE’s regulatory content and technology. It is a significant step toward creating an industry-defining regulatory compliance and risk platform that will benefit all customers and elevate the industry as a whole.”
Through this acquisition, CUBE will provide an expanded and comprehensive selection of specialized regulatory intelligence and regulatory change services, committed to excellence, quality, and highly contextualised and meaningful regulatory content for customers. By combining cutting-edge technology and subject matter expertise at scale CUBE will set a new bar for the industry in regulatory automation and content.
Chris Maguire, General Manager, Risk and Fraud, Corporates, Thomson Reuters said: “It was clear to us that CUBE had established itself as a leading regulatory intelligence provider for global enterprise clients in the financial services and insurance sectors. We wanted to ensure our customers and employees could work with an organisation that would continue to innovate and significantly invest in solutions like Thomson Reuters Regulatory Intelligence and Oden. We are working tirelessly to ensure a seamless and value-enhancing transition for customers and employees, and we are looking forward to working with the CUBE team during this transition.” 
Christopher Fielding, Hg, said: “We’re delighted to further extend our market reach, bringing in two high quality and complementary global businesses to the CUBE platform.”
Thomas Martin, Hg, added: “We see these acquisitions as enabling further innovation in the regulatory intelligence and change management sector, leading to strengthened demand for these quality solutions across the globe.”
The terms of the transaction will not be disclosed.
About CUBE
CUBE provides a highly comprehensive and robust source of classified, and meaningful AI-driven regulatory data to power its Automated Regulatory Intelligence (ARI) and Regulatory Change Management (RCM) solutions. CUBE’s purpose-built regulatory technology including its AI engine (RegBrain) and software platform (RegPlatform) tracks, analyses, and monitors laws, rules, and regulations in every country and in every published language to create an always up-to-date regulatory footprint that transforms visibility and compliance capability for customers across the globe.
With operations across Europe, North America, Canada, Asia, and Australia, CUBE serves a diverse and global base of customers and partners including the largest financial institutions in the world who leverage CUBE’s platform to streamline their complex regulatory intelligence and change management processes.
Following the strategic partnership with Hg in March 2024, CUBE announced the acquisition of US-based Reg-Room in May 2024.
About Hg
Hg supports the building of sector-leading enterprises that supply businesses with critical software applications or workflow services, delivering a more automated workplace for their customers.
This industry is characterised by digitisation trends that are in early stages of adoption and are set to transform the workplace for professionals over decades to come. Hg’s support combines deep end-market knowledge with world class operational resources, together providing compelling support to entrepreneurial leaders looking to scale their business – businesses that are well invested, enduring and serve their customers well.
With a vast European network and strong presence across North America, Hg’s 400 employees and around $70 billion in funds under management support a portfolio of around 50 businesses, worth over $140 billion aggregate enterprise value, with over 110,000 employees, consistently growing revenues at more than 20%.
About Regulatory Intelligence
Regulatory Intelligence is a proactive, connected, and comprehensive solution that tracks and analyses regulatory changes within ~2,000 regulatory bodies and rulebooks for more than 20 countries. It enables banking, financial services, and insurance (BFSI) sectors to manage exposure to operational, regulatory, and compliance risk.
About Oden
Oden State Rules and Regulations (SR&R), Oden Policy Terminator/Sentry PT, and OdenTrack provide repositories and automated solutions for complying with state rules and regulations on the provisioning of Personal and Business Insurance in the US.

View original content:https://www.prnewswire.co.uk/news-releases/cube-acquires-global-regulatory-intelligence-businesses-from-thomson-reuters-302147604.html

Continue Reading

Artificial Intelligence

Cayman Enterprise City Publishes Socio-Economic Impact Assessment by Economist and Leading Advisor on the Caribbean, Marla Dukharan

Published

on

cayman-enterprise-city-publishes-socio-economic-impact-assessment-by-economist-and-leading-advisor-on-the-caribbean,-marla-dukharan

The Impact of Cayman Enterprise City’s Socio-Economic Development Project Nears USD $1 Billion
GRAND CAYMAN, Cayman Islands, May 16, 2024 /PRNewswire/ — Cayman Enterprise City (CEC) has released a Socio-Economic Impact Assessment by Marla Dukharan. The report illustrates that CEC is increasing its impact by supporting higher earnings for Caymanians and is driving a shift towards a knowledge-based economy by focusing on high productivity sectors. The release by Dukharan reads, “Caymanian resourcefulness and private sector-led innovation have been the driving force behind the islands’ outstanding socio-economic success. Cayman Enterprise City underpins the next generation of Cayman innovation and dynamism.”

With an economic impact of USD $130 million in 2023, contributing just under USD $1 billion to the local economic activity in 12 years since inception, “CEC is helping the nation to diversify economically, in terms of sectors and jobs, ensuring locals have economic and employment opportunities that match the nation’s progress,” the report reads.
The CEC socio-economic development project is now home to 352 Special Economic Zones Companies (SEZCos), many of which are globally recognised institutions led by top executives and industry experts. “CEC member companies are providing high-value employment with salaries exceeding those typically found outside of the special economic zone,” said Charlie Kirkconnell, Chief Executive Officer at CEC. “The CEC community is fully invested in Cayman and the report illustrates that the CEC socio-economic development project is making a very significant impact on Cayman’s economy and community.”
“As CEC continues to grow, it continues to create significant employment and entrepreneurial opportunities for Caymanians and we encourage anyone that might be interested in finding out how they might get involved, whether as a member of the community and/or as a volunteer in our Enterprise Cayman non-profit organisation (NPO).”
77% of Caymanian-held jobs at CEC member companies, are in sectors with high social returns and increasing global demand. “By putting skills first and prioritizing learning, CEC is enabling new industries to take root,” the release by Dukharan reads.
CEC, through its Enterprise Cayman NPO, is a first-mover in private sector-facilitated education and training in the Caribbean, making it a leading force to boost youth participation in the economy. By offering training in specialised skills, Enterprise Cayman is helping to close the gap in higher education and earnings for Caymanians. “Through Enterprise Cayman we’ve set out to strategically support meaningful employment and entrepreneurial opportunities for Caymanians, by providing internship and mentorship opportunities, by hosting skill-building and career focused training, and by providing invaluable networking and community engagement opportunities,” said Kirkconnell.
In 2023 individuals took advantage of 4,226 opportunities to participate in education, training, and career development events and, since launching entrepreneurial programming in 2021, Enterprise Cayman has worked with 41 new Cayman-born business ventures. “We’re helping to develop a local talent pool that meets the demand of Cayman’s growing digital innovation and technology sectors while, in parallel, offering exciting opportunities for individuals to launch new business ventures within an innovative business environment,” said Kirkconnell.  
With CEC’s new campus and state-of-the-art facilities, Signal House, the project “holds the promise of deep, continued economic impact,” the report concludes.
To access CEC’s economic impact assessments and Enterprise Cayman’s annual reports please visit https://www.enterprisecayman.ky/reports. For more information on how to get involved and for upcoming programmes and events visit www.enterprisecayman.ky. 
Website: www.caymanenterprisecity.com LinkedIn: @CaymanEnterpriseCityTwitter:  @CEC_CaymanInstagram: @CaymanEnterpriseCityFacebook: @CaymanEnterpriseCityYouTube: @ceccayman
About Cayman Enterprise City 
Cayman Enterprise City (CEC) is an award-winning development project which consists of three special economic zones (SEZs) focused on attracting knowledge-based and specialised-services businesses to set up a genuine physical presence in the Cayman Islands. The zones included within CEC are Cayman Tech City, Cayman Commodities & Derivatives Centre, and Cayman Maritime & Aviation City. With a dedicated Government Authority, licensing fee concessions and guaranteed fast-track processes, CEC enables international companies to quickly and efficiently establish a Cayman Islands office, which in turn enables them to generate active business income within a tax neutral environment.
About Enterprise Cayman 
Enterprise Cayman is a non-profit organisation (NPO) powered by Cayman Enterprise City in partnership with Cayman Islands’ special economic zone companies (SEZCos). The organisation, which applies the Theory of Change (TOC) methodology, provides Caymanians and residents with access to high-quality learning experiences and opportunities to develop and launch new business ventures, to pursue careers within the technology and innovation sectors, and to join a dynamic network of industry professionals. Let’s grow the next generation of Caymanian innovators and entrepreneurs with Enterprise Cayman!
Logo: https://mma.prnewswire.com/media/1317764/2860789/Cayman_Enterprise_City_Logo.jpg
FOR MORE INFORMATION:Contact: Kaitlyn Elphinstone  Email: [email protected]  

View original content:https://www.prnewswire.co.uk/news-releases/cayman-enterprise-city-publishes-socio-economic-impact-assessment-by-economist-and-leading-advisor-on-the-caribbean-marla-dukharan-302148206.html

Continue Reading

Artificial Intelligence

Strava Unveils New Chapter of Accelerated Product Development at Brand’s Flagship Event

Published

on

strava-unveils-new-chapter-of-accelerated-product-development-at-brand’s-flagship-event

The Company introduces increased product velocity, leveraging advancements in Artificial Intelligence, in service of its vision of a world connected through movement 
LOS ANGELES, May 16, 2024 /PRNewswire/ — Strava, the leading digital community for active people with more than 125 million athletes, today showcased its latest initiatives and product developments at its annual event, Camp Strava. With the theme of Progress, Together company leaders announced how the platform will empower its global community to make progress in the way they explore, move, and connect on Strava.

“Strava is gaining momentum to realize our vision of a world connected through movement,” said Michael Martin, chief executive officer of Strava. “We are focused on two fundamental shifts to accelerate how we deliver value to 125 million people globally– building for women and leveraging Artificial Intelligence – which will unlock new community-and-partner-powered experiences across the platform.”
A New Era of Product VelocityStrava, with new leaders at the helm, is ushering in its next era of product velocity. The company listened closely to feedback from its global community and announced three of the most requested features coming to the platform by the end of the year.
The first of these updates, AI-enabled Leaderboard Integrity, will harness machine learning to automatically flag irregular, improbable, or impossible activities recorded to the platform. Trained by millions of activities, this feature allows all users on Strava to play fair and have more fun.
Additionally, the company announced a new Family Plan Subscription, the sister of the company’s Student Plan. With Family Plan, it’s easier to make a fitness commitment with your community by sharing an annual subscription with up to three other people – friends, family, or fitness family. Launching in select countries this summer, with plans to roll out globally by the end of the year, Strava’s newest annual subscription option offers the best value for groups (up to four), with a discount off the regular subscription price for each member.
Strava also implemented an updated design system, an initiative that is integral in driving a heightened pace of product innovation at the company. Through this work, Strava announced the launch of one of the company’s most requested features, Dark mode. Dark mode will improve the in-app experience for all users, reducing eye strain and improving accessibility while they record activity or scroll through the feed. Athletes can expect a rollout later this summer with options to keep their mobile settings always dark, always light, or match their device settings.
Company leaders highlighted several other features and updates to current products like Flyover, with its next iteration offering an overlay with activity stats and off-platform sharing capabilities. The overlay is available today for Strava subscribers and an off-platform sharing option will be released later this year.
Build for Her, Build for ManyStudies show that women of all ages participate in sports at a far lower rate than men, and overall, despite wanting to be active, find less time to dedicate to an active lifestyle. As the company continues on its mission to motivate people to live their best active lives, building for women on the platform will ultimately serve everyone in the Strava community. Several new features and initiatives were announced as a part of this strategic focus, which includes:
Night Heatmaps: Night Heatmaps show only activities between sundown and sunrise – so athletes can get an idea of which roads, trails, and paths are well-trafficked after hours. Since Night Heatmaps filter for after-hours routes, it can be a helpful tool for female athletes training before sunrise and after sunset.Quick Edit: For active women, having control over what is shared with the Strava community that cheers them on – like what time a run is logged – is important. Quick Edit makes it easier to make the most common edits – like activity name, and privacy settings so you can hide your start time, your map, or other workout stats.Strive for More®: The company announced a new phase of its Strive for More® initiative, created in 2022 to promote and support women in movement and sport. Today, Strava unveiled an official partnership with media company TOGETHXR to encourage more women to watch – and play – women’s sports. As part of the partnership, Strava will also donate $100,000 to the Alex Morgan Foundation, started by co-founder of TOGETHXR, Alex Morgan, to support their mission to help girls and women find confident paths forward in sports and life.Athlete IntelligenceToday, Strava announced the start of an accelerated product roadmap, outlining how Strava will implement the latest technological enhancements in AI and machine learning, to transform the athlete experience.
One key advancement to the platform includes the company’s latest development, Athlete Intelligence. Strava is introducing its beta AI-powered feature which turns each subscriber’s training data into an easily digestible summary that contextualizes their accomplishments and fitness goals. Unlike other AI-powered training services, Strava connects with thousands of devices, wearables, and fitness apps, so an athlete’s insights can consider their entire fitness story across multiple sports and modalities.
The features shared at Camp Strava will be released on a rolling basis through the end of the year. To view the full list of product releases and further details, visit www.press.strava.com.
For more information on Strava, to create a free account, or to start a free subscription trial visit www.strava.com.
About Strava Strava is the leading digital community for active people with more than 125 million athletes, in more than 190 countries. The platform offers a holistic view of your active lifestyle, no matter where you live, which sport you love and/or what device you use. Everyone belongs on Strava when they are pursuing an active life. Join the community, find motivation and discover new experiences with a Strava subscription. 
Visit www.strava.com for more information and connect with Strava on Instagram, Twitter, Facebook, YouTube and LinkedIn.
Media Contact: [email protected]
 
Photo – https://mma.prnewswire.com/media/2413914/Darkmode_STRAVA.jpgPhoto – https://mma.prnewswire.com/media/2413915/Flyover_STRAVA.jpg Photo – https://mma.prnewswire.com/media/2413913/Athlete_Intelligence_STRAVA__INC.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/strava-unveils-new-chapter-of-accelerated-product-development-at-brands-flagship-event-302147068.html

Continue Reading

Trending